Group Information: A complete list of the members of the Diabetic Retinopathy Clinical Research Network (DRCR.net) who participated in this protocol are listed in the eAppendix in the Supplement.
Submitted for Publication: July 2, 2013; final revision received February 26, 2014; accepted March 3, 2014.
Published Online: July 24, 2014. doi:10.1001/jamaophthalmol.2014.1698.
Study concept and design: S. B. Bressler, Chalam, N. M. Bressler, Saggau.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: S. B. Bressler, Edwards, Glassman, Saggau, Plous.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Edwards, Glassman, Melia, Saggau, Plous.
Obtained funding: N. M. Bressler, Glassman.
Administrative, technical, or material support: Chalam, N. M. Bressler, Jaffe.
Study supervision: S. B. Bressler, N. M. Bressler, Melia, Saggau.
Conflict of Interest Disclosures: A complete list of all DRCR.net financial disclosures is at http://www.drcr.net. Dr S. B. Bressler reports serving as a consultant to GlaxoSmithKline and receiving clinical or laboratory research grants from Bausch & Lomb, Bayer, Emmes, Boehringer-Ingelheim, Notal Vision, Novartis, Regeneron, Thrombogenics, and sanofi-aventis. Dr N. M. Bressler reports receiving clinical or laboratory research grants from Bayer, Genentech, and Regeneron; providing expert testimony for Novartis; and receiving funding from Emmes. Dr N. M. Bressler also reports that grants to investigators at The Johns Hopkins University are negotiated and administered by the institution (eg, the School of Medicine) that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored projects are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the projects. Dr N. M. Bressler is principal investigator of grants at The Johns Hopkins University sponsored by the following entities (not including the National Institutes of Health): Abbott Medical Optics, Allergan, Bausch & Lomb, Bristol-Meyers Squibb, Carl Zeiss Meditec, EMMES Corporation, ForSight Labs LLC, Genentech, Genzyme Corporation, Lumenis, Notal Vision, Novartis, and Regeneron. Dr Jaffe reports serving as a consultant to Alcon, Heidelberg Engineering, Neurotech, and Novartis. No other disclosures were reported.
Funding/Support: The present study was supported through a cooperative agreement from the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services grants EY14231, EY023207, and EY018817.
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Dr N. M. Bressler is the editor of JAMA Ophthalmology. He was not involved in the editorial evaluation or decision to accept this article for publication.